Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Adenosine signaling contributes to ethanol-induced fatty liver in mice
Zhongsheng Peng, … , Giuseppe Resta, Bruce N. Cronstein
Zhongsheng Peng, … , Giuseppe Resta, Bruce N. Cronstein
Published February 16, 2009
Citation Information: J Clin Invest. 2009;119(3):582-594. https://doi.org/10.1172/JCI37409.
View: Text | PDF | Corrigendum
Research Article Gastroenterology

Adenosine signaling contributes to ethanol-induced fatty liver in mice

  • Text
  • PDF
Abstract

Fatty liver is commonly associated with alcohol ingestion and abuse. While the molecular pathogenesis of these fatty changes is well understood, the biochemical and pharmacological mechanisms by which ethanol stimulates these molecular changes remain unknown. During ethanol metabolism, adenosine is generated by the enzyme ecto-5′-nucleotidase, and adenosine production and adenosine receptor activation are known to play critical roles in the development of hepatic fibrosis. We therefore investigated whether adenosine and its receptors play a role in the development of alcohol-induced fatty liver. WT mice fed ethanol on the Lieber-DeCarli diet developed hepatic steatosis, including increased hepatic triglyceride content, while mice lacking ecto-5′-nucleotidase or adenosine A1 or A2B receptors were protected from developing fatty liver. Similar protection was also seen in WT mice treated with either an adenosine A1 or A2B receptor antagonist. Steatotic livers demonstrated increased expression of genes involved in fatty acid synthesis, which was prevented by blockade of adenosine A1 receptors, and decreased expression of genes involved in fatty acid metabolism, which was prevented by blockade of adenosine A2B receptors. In vitro studies supported roles for adenosine A1 receptors in promoting fatty acid synthesis and for A2B receptors in decreasing fatty acid metabolism. These results indicate that adenosine generated by ethanol metabolism plays an important role in ethanol-induced hepatic steatosis via both A1 and A2B receptors and suggest that targeting adenosine receptors may be effective in the prevention of alcohol-induced fatty liver.

Authors

Zhongsheng Peng, Pier Andrea Borea, Tuere Wilder, Herman Yee, Luis Chiriboga, Michael R. Blackburn, Gianfranco Azzena, Giuseppe Resta, Bruce N. Cronstein

×

Figure 5

Adenosine A1 and A2B agonists promote fat accumulation in a cultured murine hepatocyte cell line (AML-12 cells).

Options: View larger image (or click on image) Download as PowerPoint
Adenosine A1 and A2B agonists promote fat accumulation in a cultured mur...
Cells were treated with adenosine receptor agonists or antagonists or their combination (A1 receptor agonist CPA, 1 μM; DPCPX, 1 μM; A2A receptor antagonist ZM 241385 [ZM], 1 μM; nonselective and A2B receptor agonist NECA, 10 μM; A2B receptor antagonist MRS1706, 1 μM; A3 receptor antagonist 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-( ± )-diphydropyridine-3,5-dicarboxylate [MRS1191], 1 μM) for 24 hours, then stained with Oil Red O, or collected and the cellular triglyceride content was measured. (A) Oil red O staining of AML-12 hepatocytic cells (original magnification, ×400). (B) Curve of cellular triglyceride content of AML-12 cells with CPA concentration. (C) Curve of cellular triglyceride content of AML-12 cells with NECA concentration. (D) Cellular triglyceride content of AML-12 cells after CPA or antagonists or CPA combined with antagonist treatment. (E) Cellular triglyceride content of AML-12 cells after NECA or NECA combined with antagonist treatment. The data are expressed as percentages of control (mean ± SD) from 4 independent experiments. *P < 0.01, CPA or CPA plus ZM, MRS1706, or MRS1191 or NECA or NECA plus ZM or MRS1191 versus control, respectively; **P < 0.01, CPA plus DPCPX versus CPA; #P < 0.01, NECA plus DPCPX versus control or NECA, respectively; ##P < 0.01, NECA plus MRS1706 versus NECA or NECA plus DPCPX, respectively.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts